Silver Book Fact

One study found that dopaminergenic therapies for Parkinson’s disease patients resulted in lower dyskinesias as well as lower incidences of freezing, drowsiness, and edema–resulting in better quality-of-life through symptom control.

Holloway, Robert G. et al. Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A 4-year randomized controlled trial. Arch Neurol. 2004; 61(7): 1044-53. http://archneur.ama-assn.org/cgi/content/full/61/7/1044

Reference

Title
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A 4-year randomized controlled trial
Publication
Arch Neurol
Publication Date
2004
Authors
Holloway, Robert G. et al.
Volume & Issue
Volume 61, Issue 7
Pages
1044-53
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Impact of Slowed Progression by Stage of Disease, Americans Age 65 and Older with Alzheimer’s Disease, 2050  
  • A current drug in development addresses the underlying cause of type 2 diabetes by modulating genes responsible for insulin sensitization.  
  • 2006 Medicines in Development for Neurologic Disorders  
  • 91 medicines are currently in development for Alzheimer’s disease.  
  • Medicaid Costs, 5-Year Delayed Onset